Literature DB >> 8737571

Optimization of environmental factors for the production and handling of recombinant retrovirus.

S G Lee1, S Kim, P D Robbins, B G Kim.   

Abstract

Certain steps from the production to infection of the amphotropic retroviral vector, MFG- LacZ, were optimized and the factors that affect retroviral titers were analyzed. Retroviral vector titers were highest when the culture supernatant was harvested 3 days after the producer cells had reached confluence. About a 2-fold increase in vector production was achieved at 32 degrees C compared to that at 37 degrees C. Low serum concentrations had no significant effect on the titers of virus produced by the CRIP cell line. Retroviral vectors were stable at 4 degrees C but very unstable at 37 degrees C and were quite sensitive to freezing and thawing. About 30%-50% of viral infectivity was lost during the thawing step and the loss was not recovered by the addition of commonly used cryoprotectants. Increase in viral exposure time for infection to target NIH3T3 cells was linearly proportional to the retroviral titer for up to 15 h. In addition, using DEAE-dextran in place of polybrene as a polycation during infection enhanced infection efficiency about 3-fold. The retrovirus was robust to simple ultrafiltration and its titer could be easily concentrated 16-fold. Taken together, our data suggest that at least a 100-fold increase in titer can be achieved with simple optimization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737571     DOI: 10.1007/bf00578459

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  13 in total

1.  Systemic gene expression after intravenous DNA delivery into adult mice.

Authors:  N Zhu; D Liggitt; Y Liu; R Debs
Journal:  Science       Date:  1993-07-09       Impact factor: 47.728

2.  Increased viral titer through concentration of viral harvests from retroviral packaging lines.

Authors:  R W Paul; D Morris; B W Hess; J Dunn; R W Overell
Journal:  Hum Gene Ther       Date:  1993-10       Impact factor: 5.695

3.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

4.  Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product.

Authors:  J Sap; A Muñoz; J Schmitt; H Stunnenberg; B Vennström
Journal:  Nature       Date:  1989-07-20       Impact factor: 49.962

5.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

6.  Liposome mediated gene transfer.

Authors:  R J Mannino; S Gould-Fogerite
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

7.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Construction and characterization of retroviral vectors expressing biologically active human interleukin-12.

Authors:  L Zitvogel; H Tahara; Q Cai; W J Storkus; G Muller; S F Wolf; M Gately; P D Robbins; M T Lotze
Journal:  Hum Gene Ther       Date:  1994-12       Impact factor: 5.695

9.  Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector.

Authors:  T Ohashi; S Boggs; P Robbins; A Bahnson; K Patrene; F S Wei; J F Wei; J Li; L Lucht; Y Fei
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos.

Authors:  J R Sanes; J L Rubenstein; J F Nicolas
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

View more
  7 in total

1.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

2.  Justification of continuous packed-bed reactor for retroviral vector production from amphotropic PsiCRIP murine producer cell.

Authors:  S H Kang; B G Kim; G M Lee
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

Review 3.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

4.  Construction of retroviral vectors with improved safety, gene expression, and versatility.

Authors:  S H Kim; S S Yu; J S Park; P D Robbins; C S An; S Kim
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.

Authors:  Chi-Lin Lee; Michael Chou; Bingbing Dai; Liang Xiao; Pin Wang
Journal:  Biotechnol Bioeng       Date:  2012-01-17       Impact factor: 4.530

6.  A serum-free Vero production platform for a chimeric virus vaccine candidate.

Authors:  Inn H Yuk; Gina B Lin; Hui Ju; Inesse Sifi; Yvonne Lam; Armida Cortez; Danny Liebertz; J Michael Berry; Richard M Schwartz
Journal:  Cytotechnology       Date:  2006-11-16       Impact factor: 2.058

7.  Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.

Authors:  Anthony Simmons; Robert P Whitehead; Andrey A Kolokoltsov; Robert A Davey
Journal:  Virol J       Date:  2006-02-28       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.